iPSC-Derived RPE Cell Differentiation Without Manual Cell Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating iPSCs into RPE cells are labor-intensive, require long differentiation periods, involve animal-derived components, and pose risks of tumorigenesis and immune rejection, leading to inconsistent quality and high production costs.
Innovation Solution
A directed differentiation process using pluripotent stem cells, involving specific signaling pathway manipulations with small molecules, eliminates manual selection and animal-derived components, and includes gene editing for immune-privileged iPSCs, resulting in high-purity, safe, and reproducible RPE cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If spontaneous differentiation method is used, then RPE cells can be obtained, but the differentiation period is long and quality is inconsistent
Solution Approach 1:
The patent applies parameter changes by modifying differentiation conditions through specific small molecule compounds (activators and inhibitors) to control signaling pathways. This transforms the spontaneous, uncontrolled differentiation process into a directed process with defined parameters, achieving both shortened time and consistent quality across different stem cell lines.
2Manufacturing precision
If manual selection of pigmented patches is performed, then RPE cell purity is improved, but labor intensity increases and large-scale production becomes difficult
Solution Approach 1:
The patent implements self-service by engineering stem cells with endogenous fluorescent markers that automatically label RPE cells during differentiation. This eliminates the need for manual selection, as the cells self-identify through fluorescence, enabling automated sorting and large-scale production while maintaining high purity.
Solution Approach 2:
The patent replaces the mechanical manual selection process with fluorescence-activated cell sorting (FACS), an automated optical sorting system. This substitution transforms a labor-intensive mechanical process into an automated technological process, enabling large-scale production with consistent purity.
3Reliability
If animal-derived components are used in differentiation medium, then differentiation can be achieved, but tumorigenic risk increases
Solution Approach 1:
The patent changes the chemical composition parameters of the differentiation medium by replacing animal-derived components with chemically defined alternatives containing specific small molecules. This parameter change maintains differentiation efficacy while eliminating tumorigenic risks associated with animal products.
Solution Approach 2:
The patent uses small molecule compounds that can be precisely controlled and eliminated from the final product, replacing persistent animal-derived components. These small molecules serve their function during differentiation and do not pose long-term safety risks.
4Loss of time
If allogeneic iPSC-RPE is used, then immediate treatment is possible, but immune rejection occurs requiring long-term immunosuppressants
Solution Approach 1:
The patent applies local quality by modifying specific immune-related properties of the iPSCs (such as HLA gene editing) while maintaining their differentiation potential. This localized modification creates immune-privileged cells that can be allogeneically transplanted without rejection, combining immediate availability with long-term survival.
5Reliability
If autologous iPSC-derived RPE cells are used, then immune compatibility is achieved, but production cost increases and quality is inconsistent
Solution Approach 1:
The patent creates universal iPSC lines with engineered immune-privileged properties that can serve multiple patients. These universal cells maintain immune compatibility through genetic engineering rather than requiring individual autologous differentiation, enabling standardized production with consistent quality and lower costs.
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
This invention, which pertains to the field of regenerative medicine and relates to cell therapy, provides a pluripotent stem cell-derived RPE cell, a preparation, a pharmaceutical composition, a reagent, a method, and a kit; said RPE cell is obtained through differentiation of iPSCs in an E6 medium supplemented with chemical small molecules serving as inhibitors or activators; said differentiation comprises the following stages: a neuroectodermal cell induction stage, an RPE progenitor cell induction stage, an RPE cell induction stage, and an RPE cell maturation stage. Manual removal of non-RPE-like heterogeneous cells is not required during said differentiation process, and pure RPE cells can be obtained through passaging culture.